BR0008468A - Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos - Google Patents

Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos

Info

Publication number
BR0008468A
BR0008468A BR0008468-9A BR0008468A BR0008468A BR 0008468 A BR0008468 A BR 0008468A BR 0008468 A BR0008468 A BR 0008468A BR 0008468 A BR0008468 A BR 0008468A
Authority
BR
Brazil
Prior art keywords
hormone
same
agonist
antagonist
aspects
Prior art date
Application number
BR0008468-9A
Other languages
English (en)
Inventor
Christian Grondahl
Thomas Host Hansen
Alexander Ruebig
Christa Hegele-Hartung
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR0008468A publication Critical patent/BR0008468A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MéTODO PARA FERTILIZAçãO HUMANA IN VITRO, USO DE UM HORMÈNIO HIPOTALâMICO E/OU HORMÈNIO PITUITáRIO OU DE UM AGONISTA OU ANTAGONISTA DO MESMO OU DE UM DERIVADO ATIVO DO MESMO, KIT FARMACêUTICO EM FORMA DE DOSAGEM úNICA, E, QUALQUER NOVO ASPECTO OU COMBINAçãO DE ASPECTOS". A fertilização in vitro pode ser aperfeiçoada adicionando-se um composto ativador da meiose.
BR0008468-9A 1999-02-24 2000-02-23 Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos BR0008468A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA199900255 1999-02-24
US13081699P 1999-04-23 1999-04-23
DKPA199901310 1999-09-16
PCT/DK2000/000074 WO2000050066A1 (en) 1999-02-24 2000-02-23 Treatment of infertility

Publications (1)

Publication Number Publication Date
BR0008468A true BR0008468A (pt) 2002-02-05

Family

ID=27220546

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008468-9A BR0008468A (pt) 1999-02-24 2000-02-23 Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos

Country Status (13)

Country Link
US (1) US6585982B1 (pt)
EP (1) EP1156822B1 (pt)
JP (1) JP2002537349A (pt)
KR (1) KR20010093280A (pt)
CN (1) CN1353617A (pt)
AT (1) ATE317266T1 (pt)
AU (1) AU2794100A (pt)
BR (1) BR0008468A (pt)
CZ (1) CZ20012967A3 (pt)
DE (1) DE60025905T2 (pt)
ES (1) ES2258445T3 (pt)
HU (1) HUP0200157A3 (pt)
WO (1) WO2000050066A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
BR0008536A (pt) * 1999-02-26 2001-11-06 Novo Nordisk As Usos de um meio de cultura, e de pelo menos um mas, análogo de mas ou um aditivo ou aditivos, e, processo para fertilização in vitro
AU3376501A (en) * 2000-02-25 2001-09-03 Novo Nordisk A/S Improvement of implantation rate
AU2001240624A1 (en) * 2000-02-25 2001-09-03 Novo-Nordisk A/S Improvement of implantation rate
CA2404822A1 (en) * 2000-05-18 2001-11-22 Novo Nordisk A/S Fertilization of aged oocytes
AU2001261968A1 (en) * 2000-05-25 2001-12-03 Oregon Health Sciences University Pt32 sperm protein, sperm c-yes, oocyte cytoplasmic c-yes, and uses thereof
EP1216701A1 (en) * 2000-12-22 2002-06-26 Schering Aktiengesellschaft Process to increase the concentration of meiosis-activating sterols (MAS) in the cholesterol synthesis and the use of potent inhibitors in the process
EP1245572A1 (en) 2001-03-26 2002-10-02 Schering Aktiengesellschaft Aminosterol compounds, their use in the preparation of meiosis-regulating medicaments and method for their preparation
MXPA04002257A (es) * 2001-09-12 2004-07-23 Applied Research Systems Uso de gonadotropina corionica humana (gch) y su hormona de liberacion (hl) en hiperestimulacion ovarica controlada.
AU2002324183B2 (en) * 2001-09-12 2007-10-25 Merck Serono Sa Use of hCG and LH in controlled ovarian hyperstimulation
EP1425032A2 (en) * 2001-09-12 2004-06-09 Applied Research Systems ARS Holding N.V. USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
AU2003203145A1 (en) * 2002-02-22 2003-09-09 Novo Nordisk A/S A transducer of mas signalling
JP2005518823A (ja) 2002-03-08 2005-06-30 マクギル・ユニバーシテイ 未成熟ヒト卵母細胞の体外成熟
MEP39308A (en) * 2002-06-07 2011-02-10 Ares Trading S A Chateau De Vaumarcus Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
CA3009909A1 (en) 2004-05-17 2005-12-22 The General Hospital Corporation Compositions comprising female germline stem cells and methods of use thereof
CN103893211A (zh) 2006-03-07 2014-07-02 吉塔·什罗夫 包含人胚胎干细胞和其衍生物的组合物、其使用方法和制备方法
PE20141517A1 (es) 2011-04-14 2014-10-25 Gen Hospital Corp Composiciones y metodos para transferencia de energia mitocondrial de linea germinal autologa
WO2013002880A1 (en) 2011-06-29 2013-01-03 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells
US20150272622A1 (en) 2011-12-22 2015-10-01 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563059A (en) * 1993-02-23 1996-10-08 Genentech, Inc. Use of human inhibin and human activin to increase the number of mature primate oocytes
US5716777A (en) * 1994-06-23 1998-02-10 Novo Nordisk A/S Regulation of meiosis using sterols
PL322106A1 (en) * 1995-03-06 1998-01-05 Novo Nordisk As Meiosis stimulation
AU6122696A (en) * 1995-06-23 1997-01-22 Novo Nordisk A/S Meiosis regulating compounds
PL185622B1 (pl) * 1995-06-23 2003-06-30 Novo Nordisk As Zastosowanie związku steroidowego i sposób regulacji mejozy w komórce rozrodczej ssaka
AU746878B2 (en) * 1996-12-20 2002-05-02 Novo Nordisk A/S Meiosis regulating compounds
AU8535398A (en) * 1997-06-04 1998-12-21 Akzo Nobel N.V. 17beta-allyloxy(thio)alkyl-androstane derivatives for the modulation of meiosis
US5866599A (en) * 1997-06-06 1999-02-02 Basf Aktiengesellschaft Fungicidal mixtures
EP1156821B1 (en) * 1999-02-24 2007-05-02 Novo Nordisk A/S Treatment of infertility

Also Published As

Publication number Publication date
HUP0200157A3 (en) 2002-06-28
WO2000050066A1 (en) 2000-08-31
EP1156822B1 (en) 2006-02-08
AU2794100A (en) 2000-09-14
HUP0200157A2 (hu) 2002-05-29
EP1156822A1 (en) 2001-11-28
JP2002537349A (ja) 2002-11-05
ES2258445T3 (es) 2006-09-01
US6585982B1 (en) 2003-07-01
ATE317266T1 (de) 2006-02-15
CZ20012967A3 (cs) 2001-12-12
KR20010093280A (ko) 2001-10-27
DE60025905T2 (de) 2006-09-14
DE60025905D1 (de) 2006-04-20
CN1353617A (zh) 2002-06-12

Similar Documents

Publication Publication Date Title
ATE387430T1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
PT1094781E (pt) Composições para administração transdérmica rápida e não irritante de agentes farmacologicamente activos e métodos para formulação de tais composições e sua administração
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
PL347671A1 (en) Compounds and compositions for delivering active agents
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
NO20024309D0 (no) Intradermal penetreringsmidler for topikal lokal anestetisk administrering
CA2408417A1 (en) Local anesthetic methods and kits
DE60021059D1 (de) Hydrogelpartikel formulierungen
DK0742714T3 (da) Flydende farmaceutiske præparater omfattende thyroideahormoner
BR0107869A (pt) Composições farmacêuticas eletrogiradas
NO980700D0 (no) Perifert aktive anti-hyperalgesi opiater
BRPI0413028A (pt) composto, uso de um composto, composição farmacêutica, e, kit farmacêutico
MXPA05006169A (es) Composiciones y metodos para el suministro de agentes farmacologicos.
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
BR0110079A (pt) Combinação de compostos orgânicos
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
BR0305628A (pt) Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
BR9709934A (pt) Kit de terapia de reposição hormonal e/ou contraceptivo uso de unidades de dosagem diária consistindo essecialmente de um progestogênio e processo de preparação de um sistema de liberação de droga
BR9709062A (pt) Composto, composição farmacêutica, e, uso de um composto.
BR0313388A (pt) Método para tratar, remediar ou evitar a psorìase em um paciente, uso de um composto de antagonista de cgrp, composição farmacêutica para tratamento da psorìase, e, método para identificar um composto candidato para o uso em um medicamento para tratar a psorìase
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
BR9912827A (pt) Composições tópicas compreendendo um analgésico opióide e um antagonista de nmda
YU2603A (sh) Nova kombinacija (5ht2) agonista i (5ht6) antagonista serotonina kao farmaceutska kombinacija

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1925 DE 27/11/2007.